DaVita Inc.

Report azionario NYSE:DVA

Capitalizzazione di mercato: US$15.1b

DaVita Crescita futura

Criteri Future verificati 2/6

DaVita prevede che gli utili e i ricavi cresceranno rispettivamente di 7.7% e 4.7% all'anno. Si prevede che l'EPS crescerà di 18.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 87.7% in 3 anni.

Informazioni chiave

7.7%

Tasso di crescita degli utili

18.07%

Tasso di crescita dell'EPS

Healthcare crescita degli utili19.8%
Tasso di crescita dei ricavi4.7%
Rendimento futuro del capitale proprio87.73%
Copertura analitica

Good

Ultimo aggiornamento11 May 2026

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Aggiornamento della narrazione • Jun 30

DVA: Future Margin Assumptions And GLP-1 Headwinds May Restrain Upside

DaVita's updated analyst price target has shifted to $145 from $126, reflecting analysts' revised assumptions for lower discount rates, different revenue growth expectations, higher profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on DaVita points to a mixed set of views, with some analysts revising price targets and ratings based on updated assumptions around discount rates, revenue growth, margins, and valuation multiples.
Aggiornamento della narrazione • Jun 16

DVA: Share Repurchases And GLP-1 Risks Will Shape Future Stock Economics

DaVita's analyst price target has been raised by $57, with analysts citing updated assumptions around discount rates, long term revenue growth, profit margin, and future P/E as key drivers of the revised valuation view. Analyst Commentary Recent research on DaVita highlights a cluster of upward price target revisions and an upgrade, with analysts revisiting their assumptions on discount rates, long term revenue growth, profit margins, and future P/E multiples.
Aggiornamento della narrazione • Jun 02

DVA: Share Repurchases And GLP-1 Headwinds Will Shape Future Kidney Care Economics

DaVita’s updated analyst price target holds steady at $193.71, with recent upward revisions from firms like TD Cowen, Truist, Barclays and an upgrade at Deutsche Bank. These moves reflect analysts’ focus on its refined discount rate, revenue growth outlook, profit margin assumptions and expected future P/E multiple.
Aggiornamento della narrazione • May 13

DVA: Buybacks And Revised Earnings Assumptions Will Confront Emerging GLP-1 Headwinds

DaVita's analyst price target has shifted from $151.71 to $193.71, with analysts pointing to updated assumptions for revenue growth, profit margins and future P/E multiples, along with a series of recent target hikes and an upgrade from major firms as key drivers behind the change. Analyst Commentary Recent Street research on DaVita has been active, with several firms revisiting their models and adjusting targets.
Seeking Alpha • May 07

DaVita: Improved Volumes And Tech In Focus (Rating Upgrade)

Summary DaVita Inc. is upgraded to a Buy following robust Q1 results and a 23% post-earnings stock surge. DVA's Q1 non-GAAP EPS of $2.87 beat consensus, with revenue up 6% year-over-year and management raising guidance. Mid-teens EPS growth is expected through 2026, with a 10%+ FCF yield and a modest P/E ratio supporting valuation. Technical momentum is strong, but DVA investors should monitor potential resistance in the low $200s and key upcoming events. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 28

DVA: Buybacks And Earnings Assumptions Will Shape Future Return Balance

Analysts have raised DaVita's consolidated price target by $30 to $151.71, citing updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent Street research on DaVita has centered on higher price targets and refreshed assumptions around discount rates, revenue outlook, margins and future P/E multiples.
Aggiornamento della narrazione • Apr 07

DVA: Buyback Pace And Long Term Earnings Assumptions Will Shape Future Returns

Analysts raised their DaVita price targets by up to $30, citing updated assumptions for discount rates and long term earnings multiples, while keeping core fair value drivers broadly unchanged. Analyst Commentary Recent research updates around DaVita have focused on recalibrating valuation frameworks rather than shifting the core business thesis.
Aggiornamento della narrazione • Mar 23

DVA: Ongoing Buybacks And Revised P/E Assumptions Will Shape Future Returns

DaVita’s analyst price target has been revised to $151.71, with analysts pointing to updated assumptions around the discount rate and forward P/E as key drivers of the refreshed outlook. Analyst Commentary Recent Street research on DaVita points to a cluster of higher price targets, with several firms revisiting their models around discount rates and forward P/E assumptions.
Aggiornamento della narrazione • Mar 08

DVA: Ongoing Buybacks And Repriced Execution Risk Will Shape Future Returns

Our updated analyst price target for DaVita edges higher by a few dollars to reflect slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E, generally in line with the recent series of upward target revisions from Truist, TD Cowen, UBS and Barclays. Analyst Commentary Bullish Takeaways Bullish analysts raising price targets by US$4 to US$30 signal increased confidence in DaVita's ability to execute against current expectations rather than a complete reset of the story.
Aggiornamento della narrazione • Feb 21

DVA: Buybacks And Richer P/E Assumptions Will Shape Future Return Potential

Analysts have raised their DaVita fair value estimate from $147.75 to $151.71, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E following a series of recent price target increases from major research firms. Analyst Commentary Recent price target changes from several firms point to a reappraisal of DaVita's risk and reward profile, which feeds directly into the updated fair value estimate.
Articolo di analisi • Feb 06

Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely

DaVita Inc. ( NYSE:DVA ) shares have had a really impressive month, gaining 30% after a shaky period beforehand. Not...
Aggiornamento della narrazione • Feb 05

DVA: Updated Cash Returns And Margin Assumptions Will Shape Future Upside Potential

Our DaVita view now reflects a higher fair value estimate of $147.75, up from $143.00. Analysts point to updated assumptions on discount rate, revenue growth, margin profile, and a lower future P/E as key drivers behind the price target revisions across recent Street reports.
Aggiornamento della narrazione • Jan 22

DVA: Share Repurchases And Kidney Research Pipeline Will Support Future Upside

Analysts have kept their fair value estimate for DaVita steady at US$143.00. They cited only small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their outlook.
Aggiornamento della narrazione • Jan 07

DVA: Clinical Research Pipeline And Buybacks Will Support Earnings Despite Reimbursement Headwinds

Analysts have trimmed their price target for DaVita by about $1.50 to $143, reflecting slightly higher discount rate and P/E assumptions while keeping growth and margin expectations broadly in line. What's in the News DaVita plans to unveil six new studies at the American Society of Nephrology's Kidney Week 2025 in Houston, focused on dialysis treatments, middle molecule clearance, access to transplantation and end of life care (Key Developments).
Aggiornamento della narrazione • Dec 20

DVA: Clinical Initiatives And Buybacks Will Support Earnings Despite Reimbursement Headwinds

Analysts modestly raised their price target on DaVita to about $145 per share, reflecting slightly lower discount rate assumptions and a marginally improved long term earnings outlook, while maintaining stable fair value and growth expectations. What's in the News DaVita will unveil six new clinical studies at ASN Kidney Week 2025 in Houston, including an oral presentation on GLP-1 receptor agonist use and its association with lower hospitalization rates in end stage kidney disease patients (company announcement).
Aggiornamento della narrazione • Dec 06

DVA: Hospital Fundamentals Will Support Earnings Amid Tougher Reimbursement Outlook

Analysts have modestly reduced their price target on DaVita to $140 from $145, reflecting increased concern about a more challenging policy and reimbursement environment, despite generally solid hospital fundamentals. Analyst Commentary Analyst sentiment around DaVita remains mixed, with modestly reduced price targets reflecting both confidence in the company’s operational footing and caution about the evolving reimbursement backdrop.
Aggiornamento della narrazione • Nov 22

DVA: Hospital Fundamentals And Resilient Execution Will Drive Steady Performance

DaVita’s analyst price target has been revised downward from $147.13 to $144.50, as analysts cite a cautious outlook due to anticipated policy and reimbursement challenges, despite otherwise steady hospital fundamentals. Analyst Commentary Analysts have offered a range of perspectives on DaVita following the recent adjustment to its price target.
Aggiornamento della narrazione • Nov 03

DVA: Policy Shifts And Operational Recovery Will Shape Outlook In 2025

DaVita's analyst price target has been reduced from $150.50 to $147.13, as analysts cite ongoing concerns over policy headwinds and recent operational challenges that are impacting forecasts. Analyst Commentary Analysts have updated their outlook on DaVita based on recent sector-wide developments and company-specific events.
Aggiornamento della narrazione • Oct 20

Aging Population And AI Will Reshape Dialysis Care

DaVita's analyst price target has been revised downward from $153.50 to $150.50. This change reflects ongoing concerns among analysts about reimbursement challenges and the impact of recent operational disruptions.
Aggiornamento della narrazione • Sep 04

Aging Population And AI Will Reshape Dialysis Care

Analysts have revised their outlook on DaVita to reflect lower treatment growth, reduced revenue per treatment, and ongoing operational challenges stemming from cyberattack disruptions, resulting in a consensus price target that remains unchanged at $153.50. Analyst Commentary Bearish analysts revised down treatment growth expectations due to higher missed treatment rates stemming from cyberattack disruptions.
Articolo di analisi • Aug 05

Investors Aren't Entirely Convinced By DaVita Inc.'s (NYSE:DVA) Earnings

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
Articolo di analisi • Jul 16

Slowing Rates Of Return At DaVita (NYSE:DVA) Leave Little Room For Excitement

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Seeking Alpha • Mar 17

The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin

Summary Between 2016 and 2024, DaVita's revenues grew less proportionally than the U.S. inflation. DVA has experienced difficulty enrolling more patients in its dialysis program, reporting a decline in its patients since 2019. Since 2012, the company has experienced lawsuits, which have cost approximately $1,000 million in payments and have negatively affected its reputation. The net income of DaVita increased by 50.59% between 2017 and 2024. In the last year, the company reported an 11.66% net income margin. Read the full article on Seeking Alpha
Seeking Alpha • Feb 05

DaVita: Momentum Could Fade Given High Valuation

Summary DaVita has returned ~60% over the last year, backed by superior earnings growth; however, going forward, I believe earnings growth should slow down. The Company faces headwinds from supply chain issues, higher mortality rates, and increased interest expenses, but tailwinds from lower center closure costs and Latin America acquisitions should more than offset headwinds. DVA stock is currently trading at a premium compared to the historical average. Applying a 14x PE multiple to the 2025 consensus EPS of $11.44, I estimate a fair value of $160 per share, below the current $177. Read the full article on Seeking Alpha
Seeking Alpha • Nov 14

DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation

Summary Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors, and potential policy changes. The company's recent financial performance, including a decline in net income and increased debt costs, underscores my conservative valuation approach. I assign DaVita a price target of $130/share, reflecting a cautious outlook on growth and valuation amidst industry and economic uncertainties. Read the full article on Seeking Alpha
User avatar
Nuova narrazione • Aug 22

Critical Investments And Policy Changes Propel Healthcare Innovator Towards Brighter Financial Horizons

DaVita's investments in technology and workforce initiatives aim to enhance revenue operations and patient care, contributing to future growth and profitability.

Previsioni di crescita degli utili e dei ricavi

NYSE:DVA - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202815,2361,075N/AN/A3
12/31/202714,6301,012N/AN/A7
12/31/202614,1499101,027N/A7
3/31/202613,8357561,4932,027N/A
12/31/202513,6437221,3111,887N/A
9/30/202513,3187721,2921,893N/A
6/30/202513,1618361,2881,862N/A
3/31/202512,9698601,7592,337N/A
12/31/202412,8169361,4672,022N/A
9/30/202412,6678281,4161,960N/A
6/30/202412,5248601,2691,810N/A
3/31/202412,3388169201,462N/A
12/31/202312,1406921,4912,059N/A
9/30/202311,9115961,3141,918N/A
6/30/202311,7394541,3571,967N/A
3/31/202311,6655001,0771,705N/A
12/31/202211,6105479611,565N/A
9/30/202211,6376801,1521,751N/A
6/30/202211,6278349951,607N/A
3/31/202211,6169031,4792,099N/A
12/31/202111,6199781,2891,931N/A
9/30/202111,5809841,2091,886N/A
6/30/202111,5668831,1241,802N/A
3/31/202111,5297911,1081,773N/A
12/31/202011,5517831,3041,979N/A
9/30/202011,5448321,5062,175N/A
6/30/202011,5248241,6482,333N/A
3/31/202011,4878162,1122,834N/A
12/31/201911,388705N/A2,496N/A
9/30/201911,311623N/A2,235N/A
6/30/201911,253548N/A2,011N/A
3/31/201911,300551N/A1,208N/A
12/31/201811,412616N/A1,531N/A
9/30/201811,378617N/A1,592N/A
6/30/201811,299698N/A1,679N/A
3/31/201811,110652N/A1,470N/A
12/31/201710,884909N/A1,966N/A
9/30/20177,7731,065N/A1,983N/A
6/30/20178,7321,480N/A2,016N/A
3/31/20179,7471,382N/A2,391N/A
12/31/201610,6961,038N/A1,988N/A
9/30/201614,550716N/A1,918N/A
6/30/201614,347361N/A2,061N/A
3/31/201614,065478N/A1,576N/A
12/31/20159,973323N/A1,531N/A
9/30/201513,565484N/A1,051N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di DVA ( 7.7% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di DVA ( 7.7% all'anno) cresceranno più lentamente rispetto al mercato US ( 18.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di DVA cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di DVA ( 4.7% all'anno) crescerà più lentamente rispetto al mercato US ( 12.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di DVA ( 4.7% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di DVA sarà molto alto tra 3 anni ( 87.7 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/04 07:08
Prezzo dell'azione a fine giornata2026/07/02 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

DaVita Inc. è coperta da 28 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Matthew GillmorBaird
Sarah JamesBarclays
Andrew MokBarclays